Introduction
The general term "newborn screening" is used to describe various tests that can occur during the first few hours or days of a newborn's life and which, when properly timed and performed, have the potential for preventing severe health problems, including death. Newborn screening has evolved from a relatively simple blood or urine screening test, originally used for detecting a single congenital condition, to a more comprehensive and complex screening system that can detect over 50 different conditions. 1 While typically using blood taken from a heelstick, more recent newborn screening expansion has included bedside testing to detect conditions such as hearing loss and cardiac disease. The latter 2 conditions are now included in the U.S. federally recommended uniform screening panel (RUSP) 2 and are included in some programs in other parts of the world. This report focuses on newborn bloodspot screening (NBS) commonly used to identify inborn errors of metabolism or other inherited disorders and updates screening reports that were published in 2007, outlining NBS activities in various parts of the world. [3] [4] [5] [6] [7] [8] [9] More detailed information on hearing screening can be found in an earlier issue of this Journal, 10 and information on CCHD can be found elsewhere in the current issue.
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NBS typically uses blood taken from a heelstick, absorbed onto special collection paper (similar consistency to filter paper), and transported to a special screening laboratory. 12 While hospital laboratories may be qualified to perform NBS testing in some settings, the screening laboratory is usually a specialized laboratory because of the micro-techniques used, the cost savings from centralizing the laboratory services, and improvements in quality realized when testing large quantities of specimens for relatively rare conditions. In the U.S., it is most often a special public health laboratory. In some settings, it may be part of a larger clinical genetics laboratory, and in others, particularly in developing countries, it may be in a research setting.
In order to assess NBS activities globally, we have divided the world into 5 regions: North America, Europe, Asia Pacific, Middle East and North Africa (MENA), and Latin America. Obviously missing is Sub-Saharan Africa for which little information is currently available, and limited congenital hypothyroidism (CH) and sickle cell NBS activities are ongoing. [13] [14] [15] A review of the literature and personal contacts working in Africa revealed documentation of various beginning newborn screening activities in Ghana, 16, 17 Nigeria, 18 Tanzania, 19 Angola, 20 Ethiopia, 21 Democratic Republic of Congo, 22 and South Africa. 23, 24 For the remainder of the world, we have drawn on our extensive NBS experience and contacts with NBS program managers within our respective regions to solicit recent updates in order to comprehensively describe ongoing regional NBS activities.
North America
For purposes of this report, North America is comprised of the 51 U.S. programs (50 states and the District of Columbia) and 15 Canadian programs (10 provinces and 3 territories with 1 territory, Nunavut, divided into 3 regions). Because of similar language and culture, Mexico, while a part of North America, is included in the discussion of Latin American programs. Although screening exists in some U.S. territories, little effort has been made to collect systematic data on these programs, and they are not included in the discussion here. 33 The results of SCID screening in Wisconsin (the first state to require NBS for SCID), California, New York and an 11-state consortium have been published. [34] [35] [36] [37] All but 4 state programs are at least partially fee based, and the average initial NBS screening fee has increased from about $45 in 2007 to about $76 in 2015. Despite a SACHDNC recommendation that states should consider linking birth certificates to NBS screening, the Secretary of Health and Human Services did not approve the recommendation and many state programs are still unable to accurately determine screening coverage (most "assume" at least 98% coverage). 38 While almost all states require point-of-care screening for hearing loss and CCHD, both included on the RUSP, many programs have elected to monitor hospital CCHD activities 41 and pilot data from
Missouri has been published. 42 Although X-linked adrenoleukodystrophy (X-ALD)
is not yet a part of the RUSP, a screening test has been developed and NSB for X-ALD is now required in New York Connecticut, and California, a pilot already having been completed in New York. [43] [44] [45] Laboratory quality control X-ALD NBS materials are under development. 46 Research is also ongoing to develop laboratory methods and assess public perceptions for other conditions including Fragile-X, 47, 48 spinal muscular atrophy (SMA), 49, 50 Wilson's disease, 51 and guanidinoacetate methyltransferase (GAMT) deficiency. 52 With increasing interest in NBS, and the possibility of extracting DNA from residual dried blood spot (DBS) specimens, has come an increasing awareness of privacy issues, particularly since NBS in the U.S. is legally required and consent is usually not included as part of U.S. screening protocols. The residual DBS specimens that remain after initial screening tests have been completed and reported, present storage and usage challenges. Approximately half of U.S. NBS programs discard residual specimens by 2 years and the rest retain them for more than 18 years. 53 Legal questions concerning NBS specimen storage and use have led to lawsuits in Texas and Minnesota resulting in significant policy changes in both states, 54 and another lawsuit now exists in Indiana. To help address this issue, the concerns of selected state NBS advisory committees have been assessed, and the SACHDNC has considered the issue and made general recommendations. 55, 56 As in other countries, researchers in both the U.S. and Canada have investigated parental attitudes and public perceptions concerning potential uses of residual NBS specimens in an effort to inform NBS programs and address any issues revealed. 57, 58 In Michigan, a model NBS biobank has been developed, 59 and a Newborn Screening Translational Research Network (NBSTRN) has been funded by the National Institutes of Health as one way of providing researchers with improved knowledge and access to NBS specimens in participating state NBS programs. 60 In Canada, the federal government has no formal role in newborn screening. Healthcare (and NBS) is the responsibility of the 10 provinces and 3 territories, with the notable exception of specific populations of aboriginals, inmates of federal prisons, military and newly arrived immigrants and refugees. These specific populations together make a group larger than most provinces. In the absence of pan-Canadian development and coordination of newborn screening policies and practices, individual provinces have their own advisory and decision-making processes, with varying degrees of public transparency. A recent reorganization of territorial governments across the northern tier of Canada has also had implications for NBS. In particular, the establishment of the territory of Nunavut means that NBS specimens are sent to 3 different provincial NBS labs based on historic patterns of medical services delivery.
Since 2010, when the Canadian College of Medical Geneticists took a position supporting NBS for cystic fibrosis (CF), 61 most NBS programs have included it on their screening panels. However, only 3 conditions currently are included on the screening panels in all Canadian NBS programs, phenylketonuria (PKU), CH, and medium chain acyl-CoA dehydrogenase deficiency (MCADD). The number of conditions routinely screened varies from 5 to over 30 across programs (Table 2 ). There appears to be a new focus on newborn screening collaboration and quality improvements through recurring national conferences. An attempt to create national consensus-building took place at a conference in 2007 funded by the province of Ontario, and a fresh effort took place in 2014 as a parallel meeting of the annual symposium of the Garrod Association (made up of the treatment centers for inborn errors of metabolism).
In 2013, Ontario became the first Canadian province to screen for SCID. 62 A pilot for GAMT screening is ongoing in British Columbia. 63 In addition to bloodspot screening, a urine screening program exists in Quebec offering expanded metabolic screening and considering screening for LSDs. 64, 65 As in the U.S., there has also been significant interest in the use of residual NBS specimens for research in Canada. A number of studies have been reported addressing concerns of parents, the public, and professionals. With technology moving towards less expensive high-throughput genomic testing, the possibilities of genomic NBS are being discussed, and the ethical, legal, and social implications debated. [66] [67] [68] In both
Canada and the U.S., there is increasing emphasis on the speed with which NBS specimens reach the testing laboratory and have testing results available.
Europe
Europe is considered to consist of 48 jurisdictions situated east of the Atlantic, north of or in the Mediterranean Sea and west of the Ural Mountains, but including the whole of Russia. The total population in 2012 was over 833 million with annual births of more than 9.5 million ( Table 3) . As in many parts of the world, NBS in Europe began in the mid1960s, developing from West to East, with the latest program being initiated in Bosnia-Herzegovina in 2000. 69 Four of the 48 jurisdictions are so small that screening is performed in a larger neighboring country (Liechtenstein, Andorra, San Marino, and Monaco). Several reports have been published about the progress of NBS over time, 4, [70] [71] [72] [73] including a recent summary of activities in Southeastern Europe. 74 The data in Table 3 75 Each jurisdiction is governed independently and makes its own decisions concerning conditions that should be included in NBS. Unlike the U.S. where public opinions can influence NBS policies, there is little public knowledge concerning healthcare organization in neighboring countries. As a consequence, advocacy efforts concerning health policies across borders are limited.
There are currently no policy recommendations or direct NBS oversight at the European level. However, in recent years, European best practice guidelines for cystic fibrosis NBS have been published 76 along with treatment guidelines following NBS for both cystic fibrosis (CF) and CH. [77] [78] [79] To add complexity, in some countries, e.g., Belgium, Italy, Spain, and the UK, policy making is decentralized to regions or provinces that function more or less autonomously. The result is less than 100% screening coverage for certain conditions in these countries. Since healthcare funding in Europe is typically organized within a national health service or a statutory health insurance (social security), parents do not usually have to pay a fee for NBS services. This often results in complex government financial decisions when expansion to include new conditions is considered. While each is different, public healthcare systems have defined mechanisms to assess and appraise payment for NBS and most allow for diverse stakeholder participation when considering technology effectiveness, disease severity, and treatment availability. 80 Hearing screening and CCHD screening are usually organized and financed separately from NBS. 81 As in other countries, there has been continuing interest in the storage and use of residual NBS. 82, 83 Researchers have examined various specimen stability issues. 84, 85 There has also been considerable discussion about privacy and consent. 86, 87 While there is experimentation and discussion aimed at expanding current NBS panels to include one or more LSDs, expansion is unlikely to happen on a large scale. [88] [89] [90] On the other hand, several jurisdictions are expanding their NBS panel to include SCID. [90] [91] [92] [93] [94] Over time, the European Union (EU), presently consisting of 28 countries, has established several treaties on topics to be governed or overseen by the European Commission (EU's Executive Body). Healthcare has not been included because the member states considered it to be their own responsibility (principle of subsidiarity 
Middle East and North Africa
The MENA region consists of 21 countries with a population of about 440 million with 11 million annual births. There is significant diversity between countries in population size, per capita income, health systems, insurance coverage, and newborn screening implementation. 96 Because there are high rates of consanguinity and first cousin marriages, genetic disorders are relatively common. In the past decade, a reducing (improving) infant mortality rate (IMR) has led to growing recognition of the value of NBS, and there have been a number of collaborations and educational efforts aimed at its introduction and expansion in the MENA. Table 4 summarizes MENA data and provides an overview of current NBS activities. Because of its global appeal as a condition of sufficient prevalence with cost effective and efficacious treatment, CH has usually been the first condition emphasized in MENA NBS programs. Thus, much of the NBS effort within the region has focused on continued assessment of CH screening protocols and treatment outcomes. [102] [103] [104] Because hemoglobinopathies (Hbs) and metabolic conditions are also prevalent, and in order to influence policy makers, studies within the region have often focused on the incidences of various metabolic conditions [105] [106] [107] [108] and Hbs 109, 110 (although in the case of Hbs, there is competing emphasis on prevention strategies). Several NBS cost-effectiveness studies have also been completed in various countries. [111] [112] [113] In addition to popular interest in adding MS/MS capabilities to expand metabolic screening capabilities, studies have also addressed the potential impact of adding other conditions to screening panels, including glucose-6-phosphate dehydrogenase (G6PD) deficiency, galactosemia (GAL), CAH, and CF. Successful screening experiences across the region have provided a basis for considering internal expansion and for encouraging screening activities in neighboring jurisdictions. 114 129 Total coverage exceeded 60% in 2013, except for CF which was 24%; however, for newborns born in public institutions Table 5 -Program demographics and screened conditions in Latin American screening programs.
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coverage was 94% and 31%, respectively. Currently, the national program is focused on increasing the coverage for CF and planning expansion to include piloting CAH, GAL, and MS/MS in 2015. In Panama, the national NBS program for CH and G6PD deficiency began in 2007, expanding to include GAL and PKU in 2008, and CAH and Hb more recently. 129 Screening occurs in 11 regional NBS centers of the Ministry of Health, and there is an independent program implemented by the social insurance. Together, the 2 programs cover more than 75 % of newborns. Legislation was critical to NBS success in both Paraguay and Panama. In Nicaragua, a regional NBS program was started at the National Autonomous University of Nicaragua-Leon in 2005. Initially it targeted newborns in the Northwest region, extending its scope to the rest of country's departments later. 139 Screening is exclusively for CH using cord blood, and the coverage exceeds 86%. Ecuador, Peru, and Bolivia have shown the most important advances in recent years. The national NBS program in Ecuador began in December of 2011, and included PKU, CH, CAH, and GAL, with current coverage of approximately 90% of newborns. The Universal NBS Program in Peru was created by law in 2012 with PKU, CH, CAH, GAL, CF, and hearing loss as the conditions included in the initial phase. NBS activities are carried out mainly by the Maternal Perinatal National Institute and ESSALUD, organizations belonging to the public and the private sector, respectively. Despite a law, coverage in Peru is only about 20% and screening for some conditions like CF have not yet been implemented. In Bolivia, a 2006 Ministerial Decision declared NBS to be mandatory for CH, but until now a national program has still not been implemented. Similar to Peru, Bolivia has 2 main initiatives: one in Santa Cruz in the public sector and the other in La Paz in a private hospital with departmental (provincial) coverage of 70%. Three additional public programs have recently been implemented in Chuquisaca, Cochabamba, and Tarija, so that total coverage from all programs is about 20%.
NBS in other countries in the region have not exhibited significant changes. A national NBS program was started in Guatemala in 2003, building on pilot CH NBS activities initiated with funding from the International Atomic Energy Agency in the mid-1990s; however its scope is limited only to newborns born in 2 hospitals in Guatemala City. Diseases screened include CH, PKU and CAH covering approximately 1% of newborns. In the Dominican Republic, there are only minimal NBS activities carried out on request in the private sector. Other metabolic diseases are screened by sending samples to private laboratories in USA. At present, specialists are working on a project to include screening for CH, PKU, Hb and G6PD in 2015. In El Salvador, a regional NBS program began in 2008 for newborns born exclusively in the metropolitan and paracentral regions of the country, but this program was discontinued by lack of funding. In Honduras, several different projects aimed at implementing NBS have been attempted since 2007, but none have been sustained. In Haiti, there are no known NBS activities.
Asia Pacific
The Asia Pacific region extends from New Zealand on the south to Mongolia on the north, and reaches to Pakistan in the east (see map in 2007 report). 6 Of the 138 million babies born in the world, almost half (67 million) are born in the Asia Pacific region. Countries in the region vary widely in size, economic development, and geography. There are many different languages, cultural sensitivities, and religions, each creating its own challenges in implementing NBS. In some areas, the number of births outside of hospitals approaches 80%, and literacy is very low. Despite these challenges, NBS continues to grow throughout the region. Almost 80% of the births in the Asia Pacific region occur in 5 countries-China, Indonesia, Bangladesh, India, and Pakistan. The IMR has been found to be a good predictor of when competing health issues acknowledge the need for NBS, and all countries with an IMR lower than of 7 per 1000 live births have been able to reach NBS coverage of more than 90%. 140 The number of conditions screened varies widely across the region. Several recent reports review NBS expansion activities across the region. [141] [142] [143] [144] [145] [146] [147] [148] [149] At the time or our 2007 report, 6 only Australia, New
Zealand, and Taiwan included expanded metabolic screening with MS/MS in their screening panels. 6 Since that time, other countries in the Asia Pacific region have expanded to include not only additional metabolic screening, but also a number of other conditions not in their panels at that time. The Japanese Ministry of Health and Welfare decided to expand publicly funded NBS to include inborn errors of amino acid, organic acid, and fatty acid metabolism in 2012, 150 but in most other Asian countries, patients must pay for this additional (optional) testing. There has also been increasing interest in NBS for LSDs, and significant progress with Pompe disease screening has been reported in Taiwan, [151] [152] [153] Japan, 154 and Korea. 155 Additional pilot studies in the region for other LSDs (Niemann-Pick A/B, Krabbe, Gaucher, Fabry, and Hurler syndrome) have been reported. [156] [157] [158] [159] Other conditions for which there have been ongoing NBS pilot studies include citrin deficiency, 160 SCID, 161 Fragile-X syndrome, 162 X-ALD, 44 and Wilson's disease. 163 Currently, Taiwan is the only country in the region that includes both Pompe disease and SCID in the national panel of conditions. The screening coverage rate is reported to be approximately 95% for Pompe disease and 85-88% for SCID. Pilot NBS project for LSDs, Fragile-X syndrome, and SCID is also ongoing in Australia, 164 and there is continuing interest in public perceptions, privacy, and consent issues. 165 Federal government oversight of NBS has recently surfaced as an issue 166 in Australia (programs are currently state responsibilities). 6 A working party has been tasked with developing a policy for harmonization of NBS across Australia and a mechanism for adding and removing conditions from screening panels. A final submission is due at the end of 2016.(Wiley V., 2015, personal communication) India has the most births of any country in the world, yet NBS is still not a healthcare priority. 167 While the percentage coverage from NBS has increased over years, it is still not quantifiable. Some state programs are now beginning, and a number of provincial pilots are ongoing, including some efforts in the private sector. Initiatives include BIO, CAH, CH, Fragile-X, G6PD, GAL, and MS/MS. (Kabra M., 2015, personal communication). The situation has recently been reviewed by Verma et al. 168 with suggestions to the government for screening implementation. As a first step, the authors suggest convening a central advisory committee to plan for program development. Three conditions are recommended for immediate introduction in urban hospitals (CH, CAH, and G6PD deficiency), while the recommendation for rural areas is only for CH, especially in the sub Himalayan areas. Screening with MS/MS is suggested once there is a firm infrastructure in place. The challenges noted and their potential solution are similar to those experienced in most developing programs, only they encompass a much larger screening population. 169, 170 Among the countries that lack total NBS coverage, the obstacles are usually the same: poor economies, insufficient 3 9 ( 2 0 1 5 ) 1 7 1 -1 8 7 health education, lack of government support, early hospital discharge, and large numbers of out-of-hospital births. Certain items have been identified as essential to success for sustainable programs: (1) government prioritization, (2) full or partial government financing, (3) public education and acceptance, (4) health practitioner cooperation/involvement, and (5) government participation in program institutionalization. 169, 170 Despite more than a decade of pilot testing, some countries in the region with large numbers of births, i.e., Bangladesh, Indonesia, Pakistan, and India, continue to struggle in securing government support. In order to provide information sharing and ongoing educational support, a network of developing programs has existed for several years. 170 This network continues with program reviews and goal setting as a major agenda item. A summary of regional activities is given in Table 6 . Noteworthy is the success at screening implementation in China, which now reaches over 85% of all Chinese newborns. NBS in the Philippines continues as a model for developing programs with 65% coverage, recent addition of regional comprehensive follow-up/treatment centers to its infrastructure, and implementation of expanded screening, including MS/MS screening and screening for Hbs, CF, and BIO. Based on preliminary clinical estimates, NBS for Hbs in the Philippines should identify larger numbers of thalassemia patients than seen in any other thalassemia NBS program.
Summary comments
While CH remains the most significant condition included in NBS programs worldwide due to its relatively high incidence (particularly in iodine deficient areas), readily available lowcost treatment and successful treatment results, screening for various other conditions is also of high importance. Each condition included in NBS must be carefully evaluated on the basis of medical and scientific evidence surrounding the natural history of the condition and the local ability to decrease morbidity and mortality through screening. Care must be taken in implementing new programs not to make the same mistakes made by others. Carefully planned pilot testing should always include a thorough analysis of public health impact and cost effectiveness with an eye to the future. As an example, while it is true that cord blood screening can be effective as a screening mechanism for some conditions like CH and G6PD, it is equally true that cord blood specimens cannot be reliably used for metabolic screening. So, while cord blood may be appealing for programs beginning to screen for CH or G6PD, blood spot screening is the better choice because of its increased flexibility and the high likelihood of expansion to metabolic testing at some future time.
Developing programs must continually take advantage of progress already made by others. This report has identified various regional training and support activities that have assisted in the development of new programs and the refinement of already established programs. In an effort to encourage worldwide harmonization and to provide guidance in establishing the most effective and efficient protocols, the Clinical and Laboratory Standards Institute has refocused its efforts on international NBS consensus standards and guidelines. At least 6 such documents currently exist and more are planned. [171] [172] [173] [174] [175] [176] The International Society for Neonatal Screening (ISNS) also provides support for improving NBS worldwide through its collaboration with organizations like CLSI, CDC, and others and by providing expert advice and information to developing programs. Regional ISNS meetings provide additional opportunities for collaborations. NBS programs should take advantage of these and other international efforts to improve screening quality.
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This report emphasizes the complexity of NBS and the continuing need for system-wide evaluation and improvement. It also provides information about global NBS activities and points to the importance of transparency and knowledge in achieving public support worldwide. Through shared commitment and information, we will continue to expand NBS opportunities and, as a consequence, health and life outcomes. 54, 69, 154 
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